
## Susan M Abdel-Rahman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5179183/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Utility of the 13 Câ€pantoprazole breath test as a CYP2C19 phenotyping probe for children. Clinical and Translational Science, 2022, , .	3.1	1
2	Parental understanding and attitudes following pharmacogenomic testing for pediatric neuropsychiatric patients. Pharmacogenomics, 2022, 23, 345-354.	1.3	1
3	A Pilot Comparison of High- Versus Low-Tech Palatability Assessment Tools in Young Children. Paediatric Drugs, 2021, 23, 95-104.	3.1	4
4	Genetic Predictors of Susceptibility to Dermatophytosis. , 2021, , 181-196.		0
5	Adolescent perceptions of pharmacogenetic testing. Pharmacogenomics, 2021, 22, 335-343.	1.3	6
6	Racial and Ethnic Diversity in Studies Funded Under the Best Pharmaceuticals for Children Act. Pediatrics, 2021, 147, e2020042903.	2.1	7
7	Profiling Pretomanid as a Therapeutic Option for TB Infection: Evidence to Date. Drug Design, Development and Therapy, 2021, Volume 15, 2815-2830.	4.3	25
8	A call to action: Issuing a diversity and inclusion challenge to research organizations. Clinical and Translational Science, 2021, 14, 2095-2098.	3.1	15
9	Developmental Considerations for the Use of Naltrexone in Children and Adolescents. Journal of Pediatric Pharmacology and Therapeutics, 2021, 26, 675-695.	0.5	5
10	Scholarly Productivity in Clinical Pharmacology Amid Pandemicâ€Related Workforce Disruptions: Are Men and Women Affected Equally?. Clinical Pharmacology and Therapeutics, 2021, 110, 841-844.	4.7	2
11	Examining Midâ€Upper Arm Circumference Malnutrition z â€Score Thresholds. Nutrition in Clinical Practice, 2020, 35, 344-352.	2.4	6
12	The Patientâ€Centered Future of Clinical Pharmacology. Clinical Pharmacology and Therapeutics, 2020, 107, 72-75.	4.7	6
13	Serum amoxicillin levels in young infants (0–59 days) with sepsis treated with oral amoxicillin. Archives of Disease in Childhood, 2020, 105, 1208-1214.	1.9	6
14	Design and Usability of an Electronic Health Record—Integrated, Point-of-Care, Clinical Decision Support Tool for Modeling and Simulation of Antihemophilic Factors. Applied Clinical Informatics, 2020, 11, 253-264.	1.7	8
15	Validation and human factor analysis study of an infant weight estimation device. BMC Pediatrics, 2020, 20, 30.	1.7	2
16	Impact of <i>SLCO1B1</i> Genetic Variation on Rosuvastatin Systemic Exposure in Pediatric Hypercholesterolemia. Clinical and Translational Science, 2020, 13, 628-637.	3.1	12
17	Mercy TAPE for Calculationâ€Free Height Estimation in Pediatric Rehabilitation Patients. PM and R, 2020, 12, 538-545.	1.6	3
18	Examining a New Scale for Evaluating Taste in Children (TASTY). Journal of Pediatric Pharmacology and Therapeutics. 2020, 25, 131-138.	0.5	5

Susan M Abdel-Rahman

#	Article	IF	CITATIONS
19	Naltrexone Reduces Binge Eating and Purging in Adolescents in an Eating Disorder Program. Journal of Child and Adolescent Psychopharmacology, 2019, 29, 721-724.	1.3	16
20	Facilitating Informed Permission/Assent/Consent in Pediatric Clinical Trials. Paediatric Drugs, 2019, 21, 205-214.	3.1	5
21	Assessing effectiveness of a novel mid-upper arm circumference Z-score tape in a community setting in Guatemala. Archives of Public Health, 2019, 77, 44.	2.4	8
22	User-Informed Medical Device Development: A Case Study for Pediatric Malnutrition Assessment. Global Pediatric Health, 2019, 6, 2333794X1986157.	0.7	3
23	How to Conduct Clinical Trials in Children: A Tutorial. Clinical and Translational Science, 2019, 12, 218-230.	3.1	20
24	A population pharmacokinetic model for simvastatin and its metabolites in children and adolescents. European Journal of Clinical Pharmacology, 2019, 75, 1227-1235.	1.9	5
25	Acetaminophen Protein Adducts in Hospitalized Children Receiving Multiple Doses of Acetaminophen. Journal of Clinical Pharmacology, 2019, 59, 1291-1299.	2.0	7
26	Evaluating metronidazole as a novel, safe CYP2A6 phenotyping probe in healthy adults. British Journal of Clinical Pharmacology, 2019, 85, 960-969.	2.4	4
27	Examining the Role of Precision Medicine with Oral Baclofen in Pediatric Patients with Cerebral Palsy. Current Physical Medicine and Rehabilitation Reports, 2019, 7, 40-45.	0.8	4
28	Population Pharmacokinetic Modeling of Acetaminophen Protein Adducts in Adults and Children. Journal of Clinical Pharmacology, 2019, 60, 595.	2.0	1
29	Impact of Genetic Variation on Pravastatin Systemic Exposure in Pediatric Hypercholesterolemia. Clinical Pharmacology and Therapeutics, 2019, 105, 1501-1512.	4.7	19
30	Examining the role of precision medicine with oral baclofen in pediatric patients with cerebral palsy. Current Physical Medicine and Rehabilitation Reports, 2019, 7, 40-45.	0.8	0
31	Impact of <i>SLCO1B1</i> Genotype on Pediatric Simvastatin Acid Pharmacokinetics. Journal of Clinical Pharmacology, 2018, 58, 823-833.	2.0	33
32	Evaluating Midâ€Upper Arm Circumference Zâ€Score as a Determinant of Nutrition Status. Nutrition in Clinical Practice, 2018, 33, 124-132.	2.4	30
33	Development of a UPLC-MS/MS method for quantitation of metronidazole and 2-hydroxy metronidazole in human plasma and its application to a pharmacokinetic study. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2018, 1092, 272-278.	2.3	13
34	Pharmacology of Mycobacterial Drugs in Children. Journal of Pediatric Infectious Diseases, 2018, 13, 101-112.	0.2	0
35	Comparative Performance of Pediatric Weight Estimation Techniques. Pediatric Emergency Care, 2017, 33, 548-552.	0.9	17
36	Pharmacokinetics of two 6â€mercaptopurine liquid formulations in children with acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2017, 64, e26465.	1.5	5

#	Article	IF	CITATIONS
37	Construction of Lambda, Mu, Sigma Values for Determining Midâ€Upper Arm Circumference <i>z</i> Scores in U.S. Children Aged 2 Months Through 18 Years. Nutrition in Clinical Practice, 2017, 32, 68-76.	2.4	26
38	An anthropometric survey of US pre-term and full-term neonates. Annals of Human Biology, 2017, 44, 678-686.	1.0	6
39	Genetic Predictors of Susceptibility to Dermatophytoses. Mycopathologia, 2017, 182, 67-76.	3.1	21
40	A Weight Estimation Strategy for Preterm and Full-Term Infants. Global Pediatric Health, 2017, 4, 2333794X1774877.	0.7	2
41	Design and Testing of an EHR-Integrated, Busulfan Pharmacokinetic Decision Support Tool for the Point-of-Care Clinician. Frontiers in Pharmacology, 2016, 7, 65.	3.5	25
42	Pharmacokinetic considerations when prescribing in children. International Journal of Pharmacokinetics, 2016, 1, 69-80.	0.5	13
43	Pharmacokinetic considerations in treating invasive pediatric fungal infections. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 645-655.	3.3	2
44	Intravenous busulfan dose individualization – impact of modeling approach on dose recommendation. Pediatric Transplantation, 2016, 20, 443-448.	1.0	9
45	Toward Earlier Inclusion of Pregnant and Postpartum Women in Tuberculosis Drug Trials: Consensus Statements From an International Expert Panel. Clinical Infectious Diseases, 2016, 62, 761-769.	5.8	43
46	A Simple Liquid Chromatography Tandem Mass Spectrometry Method for Quantitation of Plasma Busulfan. Methods in Molecular Biology, 2016, 1383, 79-87.	0.9	9
47	Pediatric Statin Administration: Navigating a Frontier with Limited Data. Journal of Pediatric Pharmacology and Therapeutics, 2016, 21, 380-403.	0.5	14
48	Systemic exposure to menthol following administration of peppermint oil to paediatric patients. BMJ Open, 2015, 5, e008375.	1.9	14
49	Using the Mercy Method for Weight Estimation in Indian Children. Global Pediatric Health, 2015, 2, 2333794X1456662.	0.7	19
50	Estimating Weight in Children With Down Syndrome. Global Pediatric Health, 2015, 2, 2333794X1456845.	0.7	6
51	Evaluating the Effectiveness of an Illustrated Permission/Assent Form. Journal of Immigrant and Minority Health, 2015, 17, 1504-1508.	1.6	5
52	Special Populations and Pharmacogenetic Issues in Tuberculosis Drug Development and Clinical Research. Journal of Infectious Diseases, 2015, 211, S115-S125.	4.0	27
53	Oseltamivir-Warfarin Interaction in Hypoplastic Left Heart Syndrome: Case Report and Review. Pediatrics, 2015, 135, e1333-e1336.	2.1	5
54	Development and Application of a High-Throughput Screening Method to Evaluate Antifungal Activity against Trichophyton tonsurans. Journal of Biomolecular Screening, 2015, 20, 1171-1177.	2.6	4

#	Article	IF	CITATIONS
55	Challenges in Pediatric Oral Dosing. , 2015, , 33-44.		4
56	Estimation of body weight in children in the absence of scales: a necessary measurement to insure accurate drug dosing. Archives of Disease in Childhood, 2014, 99, 570-574.	1.9	24
57	Metabolism and Disposition of Bupropion in Pregnant Baboons ( <i>Papio cynocephalus</i> ). Drug Metabolism and Disposition, 2014, 42, 1773-1779.	3.3	8
58	Evaluation of the Mercy weight estimation method in Ouelessebougou, Mali. BMC Public Health, 2014, 14, 270.	2.9	26
59	Relative Oral Bioequivalence of Two 6-Mercaptopurine (6-MP) Liquid Formulations in Children with Acute Lymphoblastic Leukemia (ALL). Blood, 2014, 124, 2242-2242.	1.4	0
60	Pharmacokinetics of Antibacterial Agents in the CSF of Children and Adolescents. Paediatric Drugs, 2013, 15, 93-117.	3.1	91
61	Acetaminophen protein adduct formation following low-dose acetaminophen exposure: comparison of immediate-release vs extended-release formulations. European Journal of Clinical Pharmacology, 2013, 69, 851-857.	1.9	41
62	Evaluation of the Mercy TAPE: Performance Against the Standard for Pediatric Weight Estimation. Annals of Emergency Medicine, 2013, 62, 332-339.e6.	0.6	52
63	Validation of an Improved Pediatric Weight Estimation Strategy. Journal of Pediatric Pharmacology and Therapeutics, 2013, 18, 112-121.	0.5	24
64	Pediatric Pharmacokinetics. Pediatrics in Review, 2013, 34, 258-269.	0.4	2
65	Pediatric Pharmacokinetics. Pediatric Clinics of North America, 2012, 59, 1001-1016.	1.8	46
66	Summary of the National Institute of Child Health and Human Development–Best Pharmaceuticals for Children Act Pediatric Formulation Initiatives Workshop–Pediatric Biopharmaceutics Classification System Working Group. Clinical Therapeutics, 2012, 34, S11-S24.	2.5	60
67	Genetic predictors of susceptibility to cutaneous fungal infections: A pilot genome wide association study to refine a candidate gene search. Journal of Dermatological Science, 2012, 67, 147-152.	1.9	29
68	An Improved Pediatric Weight Estimation Strategy. Open Medical Devices Journal, 2012, 4, 87-97.	0.3	42
69	Pharmacologic Considerations for Oseltamivir Disposition. Paediatric Drugs, 2011, 13, 19-31.	3.1	15
70	Single-dose Pharmacokinetics and Tolerability of Daptomycin 8 to 10 mg/kg in Children Aged 2 to 6 Years With Suspected or Proved Gram-positive Infections. Pediatric Infectious Disease Journal, 2011, 30, 712-714.	2.0	45
71	<i>Trichophyton tonsurans:</i> the need for enhanced infection control measures in the pediatric population. Pediatric Health, 2010, 4, 367-369.	0.3	2
72	Pharmacokinetics and Tolerability of Single-dose Intravenous Ertapenem in Infants, Children, and Adolescents. Pediatric Infectious Disease Journal, 2010, 29, 1072-1076.	2.0	13

#	Article	IF	CITATIONS
73	Divergence Among an International Population of Trichophyton tonsurans Isolates. Mycopathologia, 2010, 169, 1-13.	3.1	34
74	The Prevalence of Infections With <i>Trichophyton tonsurans</i> in Schoolchildren: the CAPITIS Study. Pediatrics, 2010, 125, 966-973.	2.1	60
75	Comparative analysis of secreted enzymes between the anthropophilic–zoophilic sister species Trichophyton tonsurans and Trichophyton equinum. Fungal Biology, 2010, 114, 429-437.	2.5	12
76	Clonal outbreak of <i>Trichophyton tonsurans</i> tinea capitis gladiatorum among wrestlers in Adana, Turkey. Medical Mycology, 2010, 48, 480-485.	0.7	41
77	Update on terbinafine with a focus on dermatophytoses. Clinical, Cosmetic and Investigational Dermatology, 2009, 2, 49.	1.8	36
78	A large outbreak of Trichophyton tonsurans among health care workers in a pediatric hospital. American Journal of Infection Control, 2009, 37, 43-48.	2.3	24
79	Griseofulvin Only Modestly Diminishes Persistence of Trichophyton tonsurans on the Scalp of Carriers. Journal of Pediatric Pharmacology and Therapeutics, 2009, 14, 94-99.	0.5	9
80	Strain Differentiation of Dermatophytes. Mycopathologia, 2008, 166, 319-333.	3.1	22
81	Examining <i>Trichophyton tonsurans </i> genotype and biochemical phenotype as determinants of disease severity in tinea capitis. Medical Mycology, 2008, 46, 217-223.	0.7	12
82	Single-Dose Pharmacokinetics of Daptomycin in Children With Suspected or Proved Gram-Positive Infections. Pediatric Infectious Disease Journal, 2008, 27, 330-334.	2.0	78
83	Multilocus Genotyping Identifies Infections by Multiple Strains of Trichophyton tonsurans. Journal of Clinical Microbiology, 2007, 45, 1949-1953.	3.9	17
84	Single-Dose Pharmacokinetics of Intravenous Itraconazole and Hydroxypropyl-β-Cyclodextrin in Infants, Children, and Adolescents. Antimicrobial Agents and Chemotherapy, 2007, 51, 2668-2673.	3.2	41
85	Tracking Trichophyton tonsurans Through a Large Urban Child Care Center: Defining Infection Prevalence and Transmission Patterns by Molecular Strain Typing. Pediatrics, 2006, 118, 2365-2373.	2.1	42
86	Pharmacokinetics of Terbinafine in Young Children Treated for Tinea Capitis. Pediatric Infectious Disease Journal, 2005, 24, 886-891.	2.0	26
87	Characterization of the ALP1 Gene Locus of Trichophyton tonsurans. Mycopathologia, 2005, 160, 265-272.	3.1	12
88	Trichophyton rubrum Tinea Capitis in a Young Child. Pediatric Dermatology, 2004, 21, 63-65.	0.9	6
89	THEINTEGRATION OFPHARMACOKINETICS ANDPHARMACODYNAMICS: Understanding Dose-Response. Annual Review of Pharmacology and Toxicology, 2004, 44, 111-136.	9.4	62
90	Comparison of Various Urine Collection Intervals for Caffeine and Dextromethorphan Phenotyping in Children. Journal of Clinical Pharmacology, 2004, 44, 708-714.	2.0	8

Susan M Abdel-Rahman

#	Article	IF	CITATIONS
91	Developmental Pharmacokinetics and Pharmacodynamics of Nizatidine. Journal of Pediatric Gastroenterology and Nutrition, 2004, 38, 442-451.	1.8	17
92	Impact of ontogeny on linezolid disposition in neonates and infants. Clinical Pharmacology and Therapeutics, 2003, 74, 413-422.	4.7	47
93	The Bioequivalence of Nizatidine (Axid®) in Two Extemporaneously and One Commercially Prepared Oral Liquid Formulations Compared with Capsule. Journal of Clinical Pharmacology, 2003, 43, 148-153.	2.0	16
94	Developmental Pharmacology — Drug Disposition, Action, and Therapy in Infants and Children. New England Journal of Medicine, 2003, 349, 1157-1167.	27.0	1,986
95	Genetic Heterogeneity in the rRNA Gene Locus of Trichophyton tonsurans. Journal of Clinical Microbiology, 2003, 41, 5478-5487.	3.9	48
96	Single-Dose Pharmacokinetics of Nizatidine (Axid®) in Children. Journal of Clinical Pharmacology, 2002, 42, 1089-1096.	2.0	9
97	A Unique Valproic Acid Ingestion. Journal of Toxicology: Clinical Toxicology, 2001, 39, 419-420.	1.5	3
98	Polymorphic exocellular protease expression in clinical isolates of Trichophyton tonsurans. Mycopathologia, 2001, 150, 117-120.	3.1	20
99	Single dose pharmacokinetics of linezolid in infants and children. Pediatric Infectious Disease Journal, 2000, 19, 1178-1184.	2.0	84
100	Single dose pharmacokinetics of pleconaril in neonates. Pediatric Infectious Disease Journal, 2000, 19, 833-839.	2.0	44
101	Stability of terbinafine hydrochloride in an extemporaneously prepared oral suspension at 25 and 4 °C. American Journal of Health-System Pharmacy, 1999, 56, 243-245.	1.0	10
102	Stability of fumagillin in an extemporaneously prepared ophthalmic solution. American Journal of Health-System Pharmacy, 1999, 56, 547-550.	1.0	3
103	Investigation of terbinafine as a CYP2D6 inhibitor in vivo. Clinical Pharmacology and Therapeutics, 1999, 65, 465-472.	4.7	69
104	Single Oral Dose Escalation Pharmacokinetics of Pleconaril (VP 63843) Capsules in Adults. Journal of Clinical Pharmacology, 1999, 39, 613-618.	2.0	37
105	Pediatrics: Treatment of Tinea Capitis. Annals of Pharmacotherapy, 1997, 31, 338-348.	1.9	43
106	Response to Initial Griseofulvin Therapy in Pediatric Patients with Tinea Capitis. Annals of Pharmacotherapy, 1997, 31, 406-410.	1.9	32
107	Oral Terbinafine: A New Antifungal Agent. Annals of Pharmacotherapy, 1997, 31, 445-456.	1.9	94